Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused…
1,678€
-4,50%
Echtzeit-Aktienkurs Mersana Therapeutics
Bid:
Ask:
Nachrichten zur Mersana Therapeutics Aktie
Mersana Therapeutics: On Hold While Waiting For Any Positive News
…
Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript
…
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on…
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on…
5 Small Biotech ETFs to Watch (Updated 2024)
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript
…
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused…
Mersana Therapeutics Q4 2023 Earnings Preview
…
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused…
Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused…
Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
…
Moderna, Bayer-backed genetic therapies company files for IPO
Metagenomi Technologies, a startup developing treatments for genetic diseases backed by Moderna Therapeutics Inc (NASDAQ:MRNA) and Bayer AG (ETR:BAYN,...…
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused…
Modernas cancer vaccine shows promise, but regulatory hurdles loom
Moderna Therapeutics Inc (NASDAQ:MRNA) revealed positive data from its second cut of the cancer vaccine for adjuvant melanoma in combination…
Moderna cancer vaccine data expected to deliver only modest upside
Moderna Therapeutics Inc (NASDAQ:MRNA)s upcoming update on its cancer vaccine trial in patients with adjuvant melanoma will only prompt a…
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on…
Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Call Transcript
…
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused…
Moderna stock plummets on 3Q loss and weak sales guidance
Moderna Therapeutics Inc (NASDAQ:MRNA) stock moved lower on Thursday after the drugmaker’s weak full-year sales forecast and a significant loss…
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused…
Mersana Therapeutics: Still In Show Me Territory
…
Mersana Therapeutics GAAP EPS of -$0.47, revenue of $10.65M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q Mersana Therapeutics, For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Mersana Therapeutics, For: Aug 08
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on…
Mersana downgraded at Baird as ovarian cancer candidate misses mark
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mersana Therapeutics Shares Plumb New Depths After UpRi Failure >MRSN
Mersana Therapeutics Shares Plumb New Depths After UpRi Failure >MRSN...…
Mersana Therapeutics Shares Plunge Premarket on UpRi Failure
Mersana Therapeutics Shares Plunge Premarket on UpRi Failure...…
Form 8-K Mersana Therapeutics, For: Jul 26
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused…
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on…
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
Mersanas (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to…
Mersana downgraded at J.P. Morgan on concerns over lead asset approval
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Aldeyra, Bioventus top healthcare gainers; Mersana, Bone Biologics among losers
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mersana-Aktie crasht nach Horror-Nachricht – AKTIONÄR-Tipp schießt hoch
Mit einem Minus von satten 60 Prozent droht den Aktionären von Mersana Therapeutics ein rabenschwarzer Tag. Das Unternehmen hat keine…
Mersana Therapeutics stock craters after FDA halts trials of ovarian cancer treatment after bleeding events
Mersana Therapeutics Inc.’s stock MRSN cratered 73% premarket Thursday, after the company announced that the U.S. Food and Drug Administration…
Mersana sheds 60% on FDA partial hold on trials for lead asset
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mersana Therapeutics Says 2 Drug Trials Put on Partial Hold
Mersana Therapeutics Says 2 Drug Trials Put on Partial Hold...…
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
UPLIFT top-line data expected by early August UPLIFT top-line data expected by early August...…
Form 8-K Mersana Therapeutics, For: Jun 08
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on…
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused…
XFRA : 0M4: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -26.83% and 62.75%, respectively, for the quarter ended March 2023.…
Form 10-Q Mersana Therapeutics, For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mersana Therapeutics GAAP EPS of -$0.52 misses by $0.09, revenue of $7.8M misses by $10.49M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Mersana Therapeutics, For: May 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mersana Therapeutics Q1 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Sutro, Mersana jump after Immunogen data for ovarian cancer therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…